Bullish Case: VS-7375's 50% confirmed ORR in second-line pancreatic cancer, FDA alignment on a chemotherapy-free first-line Phase III path opening by year-end, three planned Phase III trials, a freshly funded $250M treasury, and analyst targets of $13-$24 give VSTM real re-rating fuel. Calls outnumber puts 99% by volume, and Helium's PDF still holds a second lobe at $10-$13, implying upside optionality beyond the $8.70 spot.

Bearish Case: The stock is -11% in a week, the negative (-0.10) historical correlation to the AI forecast argues the +2.25% signal may invert, and Helium's density masses at $8 (0.228) and $6 (0.195) vs only 0.075 at $10. Dilution from the $8 offering, tolerability inferior to Revolution's Zoldonrasib (RBC), CEO transition risk, and extreme 200-500% IV on wings signal a wide, mostly downward-drifting range.

Potential Outcomes:

1. ~40%: Chop $7.50-$9.50 into January as Phase III sites open; Helium PDF peaks at $8 (0.228) and market at $8 (0.194) — falsifiable if price closes >$10 by Dec.
2. ~25%: Positive Phase III enrollment/data momentum drives a retest of $10-$12; Jan $10C delta 0.35 and Jan term-structure IV peak (165%) price this in.
3. ~20%: Post-offering drift to $6-$7 on tolerability/competition headlines; Dec $4P IV 422% and Helium's 0.195 mass at $6 support this tail.
4. ~10%: Binary KRAS catalyst (readout/ FDA update) pushes >$13 — deep 2027 wings at 300-500% IV.
5. ~5%: Collapse <$5 or squeeze >$14.

November 10, 2026